Notably, PNPLA3 GG carriers with diabetes and obesity had significantly lower VLDL-1 lipids even in the fasted state compared with CC carriers (Fig. 4D), highlighting the impact of the PNPLA3 rs738409 (p.I148M) variant in these patients at high metabolic risk. Here, PNPLA3 is linked to obesity disorder.